$EVOK
Evoke Pharma Inc

2024 Q1 Form 10-K Financial Statement

#000095017024031435 Filed on March 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $1.735M $1.676M $5.181M
YoY Change 114.15% 110.45% 106.51%
Cost Of Revenue $92.53K $59.02K $201.9K
YoY Change 82.9% -68.95% -45.5%
Gross Profit $1.643M $1.617M $4.979M
YoY Change 116.23% 166.7% 132.84%
Gross Profit Margin 94.67% 96.48% 96.1%
Selling, General & Admin $3.140M $3.482M $12.23M
YoY Change 10.24% 52.14% 27.06%
% of Gross Profit 191.09% 215.36% 245.6%
Research & Development $4.645K $22.56K $181.9K
YoY Change -93.07% -17.09% -39.52%
% of Gross Profit 0.28% 1.4% 3.65%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $3.237M $3.505M $12.61M
YoY Change 9.14% 51.33% 22.5%
Operating Profit -$1.501M -$1.888M -$7.431M
YoY Change -30.34% 10.42% -4.56%
Interest Expense $124.7K -$99.49K $500.0K
YoY Change 1.11% 6.47% 0.0%
% of Operating Profit
Other Income/Expense, Net -$78.60K -$361.4K
YoY Change -10.64% -17.49%
Pretax Income -$1.580M -$1.987M -$7.792M
YoY Change -29.57% 10.21% -5.25%
Income Tax
% Of Pretax Income
Net Earnings -$1.580M -$1.987M -$7.792M
YoY Change -29.57% 10.21% -5.25%
Net Earnings / Revenue -91.03% -118.58% -150.41%
Basic Earnings Per Share -$0.17 -$2.33
Diluted Earnings Per Share -$0.17 -$0.59 -$2.33
COMMON SHARES
Basic Shares Outstanding 8.478M 3.343M 3.343M
Diluted Shares Outstanding 9.082M 3.343M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.703M $4.739M $4.739M
YoY Change 18.14% -51.85% -51.85%
Cash & Equivalents $9.700M $4.700M $4.739M
Short-Term Investments
Other Short-Term Assets $6.312K $47.53K $932.6K
YoY Change -45.36% 311.5% -3.31%
Inventory $588.8K $481.8K $481.8K
Prepaid Expenses $704.2K $885.0K
Receivables $1.452M $673.1K $673.1K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $12.45M $6.827M $6.827M
YoY Change 25.19% -41.76% -41.76%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $0.00
YoY Change -100.0% -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $241.6K $241.6K
YoY Change
Total Long-Term Assets $0.00 $241.6K $241.6K
YoY Change -100.0% 87.21% 87.2%
TOTAL ASSETS
Total Short-Term Assets $12.45M $6.827M $6.827M
Total Long-Term Assets $0.00 $241.6K $241.6K
Total Assets $12.45M $7.069M $7.069M
YoY Change 24.05% -40.36% -40.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.954M $1.712M $1.712M
YoY Change 64.76% 83.21% 83.21%
Accrued Expenses $265.9K $1.324M $1.324M
YoY Change -45.92% 83.83% 83.83%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $8.957M $3.036M $3.036M
YoY Change 433.91% 83.48% 83.48%
LONG-TERM LIABILITIES
Long-Term Debt $5.000M $5.000M $5.000M
YoY Change 0.0% 0.0% 0.0%
Other Long-Term Liabilities $1.737M $1.612M $1.612M
YoY Change 40.58% 44.95% 44.95%
Total Long-Term Liabilities $6.737M $6.612M $6.612M
YoY Change 8.04% 8.18% 8.18%
TOTAL LIABILITIES
Total Short-Term Liabilities $8.957M $3.036M $3.036M
Total Long-Term Liabilities $6.737M $6.612M $6.612M
Total Liabilities $8.957M $9.648M $9.648M
YoY Change 13.19% 24.22% 24.22%
SHAREHOLDERS EQUITY
Retained Earnings -$125.0M -$123.4M
YoY Change 6.05% 6.74%
Common Stock $128.5M $120.9M
YoY Change 7.08% 0.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.497M -$2.580M -$2.580M
YoY Change
Total Liabilities & Shareholders Equity $12.45M $7.069M $7.069M
YoY Change 24.05% -40.36% -40.36%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$1.580M -$1.987M -$7.792M
YoY Change -29.57% 10.21% -5.25%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.579M -$1.106M -$4.985M
YoY Change 58.16% -55.87% -24.42%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.543M -119.3K -119.3K
YoY Change -101.64%
NET CHANGE
Cash From Operating Activities -2.579M -1.106M -4.985M
Cash From Investing Activities
Cash From Financing Activities 7.543M -119.3K -119.3K
Net Change In Cash 4.963M -1.225M -5.104M
YoY Change -404.33% -51.11% -830.24%
FREE CASH FLOW
Cash From Operating Activities -$2.579M -$1.106M -$4.985M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001403708
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
CY2023 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-36075
CY2023 dei Entity Registrant Name
EntityRegistrantName
Evoke Pharma, Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8447886
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
420 Stevens Avenue
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 230
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Solana Beach
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92075
CY2023 dei City Area Code
CityAreaCode
858
CY2023 dei Local Phone Number
LocalPhoneNumber
345-1494
CY2023 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2023 dei Trading Symbol
TradingSymbol
EVOK
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
5300000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8477801
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 evok Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
CY2023Q4 evok Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3343070
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3343070
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 dei Auditor Firm
AuditorFirmId
243
CY2023 dei Auditor Name
AuditorName
BDO USA, P.C.
CY2023 dei Auditor Location
AuditorLocation
San Diego, California
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4739426
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9843699
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
673071
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
624832
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
885040
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
952954
CY2023Q4 us-gaap Inventory Net
InventoryNet
481840
CY2022Q4 us-gaap Inventory Net
InventoryNet
289378
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
47532
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
11551
CY2023Q4 us-gaap Assets Current
AssetsCurrent
6826909
CY2022Q4 us-gaap Assets Current
AssetsCurrent
11722414
CY2023Q4 us-gaap Deferred Costs
DeferredCosts
241637
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
129074
CY2023Q4 us-gaap Assets
Assets
7068546
CY2022Q4 us-gaap Assets
Assets
11851488
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1711778
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
934312
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1324010
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
591158
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
129074
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3035788
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1654544
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
5000000
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
5000000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
1612295
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
1112295
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
6612295
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
6112295
CY2023Q4 us-gaap Liabilities
Liabilities
9648083
CY2022Q4 us-gaap Liabilities
Liabilities
7766839
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3343070
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3343070
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
334
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
334
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
120859567
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
119731458
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-123439438
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-115647143
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2579537
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4084649
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7068546
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11851488
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5180630
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2508645
CY2023 evok Cost Of Goods Sold Expenses
CostOfGoodsSoldExpenses
201879
CY2022 evok Cost Of Goods Sold Expenses
CostOfGoodsSoldExpenses
370394
CY2023 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
181907
CY2022 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
300789
CY2023 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12227735
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9623599
CY2023 us-gaap Operating Expenses
OperatingExpenses
12611521
CY2022 us-gaap Operating Expenses
OperatingExpenses
10294782
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-7430891
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-7786137
CY2023 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
138596
CY2022 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
62007
CY2023 us-gaap Interest Expense
InterestExpense
500000
CY2022 us-gaap Interest Expense
InterestExpense
500000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-361404
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-437993
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-7792295
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-8224130
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.33
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.33
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.62
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.62
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3343070
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3343070
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3143626
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3143626
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
3555094
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1458709
CY2022 evok Payment Of At Market Offering Costs
PaymentOfAtMarketOfferingCosts
148993
CY2022 evok Issuance Of Common Stock From At The Market Offerings Value
IssuanceOfCommonStockFromAtTheMarketOfferingsValue
7294976
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-8224130
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4084649
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2579537
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1128109
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-7792295
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-7792295
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-8224130
CY2023 evok Non Cash Lease Expense
NonCashLeaseExpense
129074
CY2022 evok Non Cash Lease Expense
NonCashLeaseExpense
37025
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
1128109
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
1458709
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
48239
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
329639
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-31932
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
29208
CY2023 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
192462
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
103843
CY2023 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
655126
CY2022 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
60284
CY2023 evok Accrued Compensation
AccruedCompensation
-732852
CY2022 evok Accrued Compensation
AccruedCompensation
-71840
CY2023 evok Increase Decrease In Accrued Interest Payable
IncreaseDecreaseInAccruedInterestPayable
500000
CY2022 evok Increase Decrease In Accrued Interest Payable
IncreaseDecreaseInAccruedInterestPayable
500000
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-129074
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-37025
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4984977
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6595987
CY2022 evok Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
7443969
CY2022 evok Payment Of At Market Offering Costs
PaymentOfAtMarketOfferingCosts
148993
CY2023 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
119296
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-119296
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7294976
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5104273
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
698989
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9843699
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9144710
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4739426
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9843699
CY2023 evok Public Offering Costs Included In Accounts Payable And Accrued Expenses
PublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
122340
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
153671
CY2023 evok Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2007-01
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4700000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
1
CY2022Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-12 reverse stock split
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
1
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
2100000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentrations of Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in a federally insured financial institution in excess of federally insured limits. The Company has established guidelines designed to maintain safety and liquidity, has not experienced any losses in such accounts and believes the exposure to significant risk to the cash balance is minimal.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company relies on contract research organizations (“CROs”) and consultants to assist with ongoing regulatory activities. If the CROs and consultants are unable to continue their support, this could adversely affect the Company’s operations.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, the Company relies on third-party manufacturers for the production of Gimoti. If the third-party manufacturers are unable to continue manufacturing Gimoti, or if the Company loses one of its sole source suppliers used in its manufacturing processes, the Company may not be able to meet any development needs or commercial supply demand for Gimoti, and the development and/or commercialization of Gimoti could be materially and adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company also relies on a dedicated third-party sales team to sell Gimoti. If such third-party organization is unable to continue serving as a dedicated sales team, the commercialization of Gimoti could be materially and adversely affected.</span></p>
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2023 evok Bad Debt Expense
BadDebtExpense
0
CY2022 evok Bad Debt Expense
BadDebtExpense
0
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
361000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
239000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
121000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
50000
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
624232
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
491851
CY2023 evok Lease Commencement Date
LeaseCommencementDate
2017-01-01
CY2023 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2023 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2023-10-31
CY2023 evok Operating Lease Incremental Borrowing Rate
OperatingLeaseIncrementalBorrowingRate
0.10
CY2023Q4 us-gaap Lessor Operating Lease Term Of Contract
LessorOperatingLeaseTermOfContract
P12M
CY2023Q4 evok Lease Commencement Date
LeaseCommencementDate
2023-11-01
CY2023Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2024-10-31
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
146000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
39000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
63000
CY2023Q4 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P0Y9M29D
CY2022Q4 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P0Y9M29D
CY2007Q2 evok Research And Developments In Process
ResearchAndDevelopmentsInProcess
650000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3343070
CY2023 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock is entitled to one vote. The holders of the common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors of the Company.
CY2023 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2022 evok Issuance Of Common Stock From Warrant Exercise Shares
IssuanceOfCommonStockFromWarrantExerciseShares
0
CY2022 evok Class Of Warrant Or Right Number Of Securities Expired
ClassOfWarrantOrRightNumberOfSecuritiesExpired
139972
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1194717
CY2023Q2 evok Share Based Compensation Arrangement By Share Based Payment Award Expiration Month And Year
ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationMonthAndYear
2033-03
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
P10Y
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
153750
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
78247
CY2023 evok Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Date Intrinsic Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingDateIntrinsicValue
1.05
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.42
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.86
us-gaap Stock Issued During Period Shares Period Increase Decrease
StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
168333
CY2023Q4 evok Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized For Employee Stock Purchase Plan
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForEmployeeStockPurchasePlan
145381
CY2023 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0
CY2022 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
1128109
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
1458709
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1100000
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P0Y9M
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
624232
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
491851
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
547838
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
146497
CY2023Q4 evok Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized For Employee Stock Purchase Plan
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForEmployeeStockPurchasePlan
145381
CY2022Q4 evok Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized For Employee Stock Purchase Plan
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForEmployeeStockPurchasePlan
37048
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1317451
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
675396
CY2023 evok Minimum Age Of Employee To Participate In Defined Benefit Plan
MinimumAgeOfEmployeeToParticipateInDefinedBenefitPlan
P21Y
CY2022 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2023 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
3000
CY2022 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2023Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.03
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.01
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.02
CY2023 evok Effective Income Tax Rate Reconciliation Operating Loss And Tax Credits Other
EffectiveIncomeTaxRateReconciliationOperatingLossAndTaxCreditsOther
0.16
CY2022 evok Effective Income Tax Rate Reconciliation Operating Loss And Tax Credits Other
EffectiveIncomeTaxRateReconciliationOperatingLossAndTaxCreditsOther
0.24
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.01
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.01
CY2023 evok Effective Income Tax Rate Reconciliation Deductible Expense Share Based Compensation And Other Permanent Items
EffectiveIncomeTaxRateReconciliationDeductibleExpenseShareBasedCompensationAndOtherPermanentItems
0.02
CY2023 evok Cumulative Minimum Change In Ownership Percentage For Limitation On Utilization Of Net Operating Loss Carry Forwards
CumulativeMinimumChangeInOwnershipPercentageForLimitationOnUtilizationOfNetOperatingLossCarryForwards
0.50
CY2023 evok Cumulative Change In Ownership Period
CumulativeChangeInOwnershipPeriod
P3Y
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
25800000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3600000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1839000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1825000
CY2023Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
161000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
125000
CY2022Q4 evok Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
29000
CY2023Q4 evok Deferred Tax Assets Tax Accruals And Other
DeferredTaxAssetsTaxAccrualsAndOther
294000
CY2022Q4 evok Deferred Tax Assets Tax Accruals And Other
DeferredTaxAssetsTaxAccrualsAndOther
136000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
2294000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
2115000
CY2022Q4 evok Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
29000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
29000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2294000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2086000
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
208000
CY2023 evok Percentage Of Taxable Income Offset By Tax Losses
PercentageOfTaxableIncomeOffsetByTaxLosses
0.80
CY2022 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2023 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2000000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2000000
CY2023Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0

Files In Submission

Name View Source Status
0000950170-24-031435-index-headers.html Edgar Link pending
0000950170-24-031435-index.html Edgar Link pending
0000950170-24-031435.txt Edgar Link pending
0000950170-24-031435-xbrl.zip Edgar Link pending
evok-20231231.htm Edgar Link pending
evok-20231231.xsd Edgar Link pending
evok-ex10_11.htm Edgar Link pending
evok-ex23_1.htm Edgar Link pending
evok-ex31_1.htm Edgar Link pending
evok-ex31_2.htm Edgar Link pending
evok-ex32_1.htm Edgar Link pending
evok-ex32_2.htm Edgar Link pending
evok-ex97.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img215285054_0.jpg Edgar Link pending
img215285054_1.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
evok-20231231_htm.xml Edgar Link completed
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable